Regulatory Affairs Professionals Society· @RAPSorg · X·· 2026-10-16精选AI 评分58
AI 导读
英国药品和健康产品管理局(MHRA)通过一项多年战略,目标是在人工智能与个性化医疗兴起的背景下保持以患者为中心的监管。该战略由RAPS转述,原文未披露具体措施与时间表。
推荐理由
英国监管机构通过多年战略,把AI与个性化医疗纳入患者中心监管框架,读者可据此了解其监管方向。
正文
The UK Medicines and Healthcare products Regulatory Agency has adopted a multi-year strategy aimed at ensuring continued patient-centered regulation in the era of emerging artificial intelligence and personalized medicine.
https://hubs.la/Q04BgjRK0
来源:Regulatory Affairs Professionals Society · x.com